Study on Risvutatug Rezetecan and Ivonescimab for Adults with Advanced Solid Tumors

Inclusion Criteria

• Adults aged 18 or older.
• Diagnosed with advanced or metastatic solid tumors, regardless of mutation status.
• Specific criteria for certain types of lung cancer (SCLC and NSCLC).
• At least one measurable tumor that can be tracked.
• Good overall health with a performance status of 0 or 1.
• Life expectancy of at least 3 months and able to complete at least 4 treatment cycles.
• Adequate organ function.
• Willing to use effective contraception during the study.
• For some participants, a tumor tissue sample is required for analysis.

Exclusion Criteria

• Ongoing side effects from previous treatments that haven't improved.
• Recent major surgery or serious injury.
• Active or untreated brain metastases or certain brain conditions.
• Heart rhythm issues or significant heart problems.
• Uncontrolled high blood pressure or severe cardiovascular disorders.
• History of significant bleeding or clotting disorders.
• Recent serious infections or lung diseases.
• Allergies to study drugs or similar medications.
• Recent cancer treatments or ongoing need for certain medications.
• Significant kidney problems or other serious health conditions.